Qiagen to launch new test to aid treatment of prostate cancer

Qiagen has announced plans to commercialise a new test for use in guiding prostate cancer treatment decisions.

The AdnaTest Prostate Cancer Panel AR-V7, which is currently only available for research use, will soon be made widely accessible for use in the detection of the androgen receptor splice variant 7 (AR-V7) from liquid biopsies.

This technique allows users to investigate resistance to potential drugs for advanced prostate cancer, with the method for detecting the AR-V7 biomarker originally developed by Johns Hopkins University scientists.

Qiagen has acquired an exclusive worldwide licence from the university for the detection of all sample and cell types through nucleic acid tests, such as polymerase chain reaction or next-generation sequencing.

Thierry Bernard, senior vice-president and head of Qiagen's molecular diagnostics business, said: "We are pleased to partner with the pioneering researchers at Johns Hopkins in developing this workflow. We plan to make the AdnaTest kit commercially available this year as a sample-to-insight solution for clinical researchers."

The firm acquired the AdnaTest technology, used for detecting RNA expression from circulating tumour cells obtained from blood samples as non-invasive liquid biopsies, back in 2015.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.